References

Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial

10.1038/s41591-024-03263-5 · 2024 · External reference

Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes

10.1056/nejmoa2025845 · 2020 · External reference

FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

10.1093/eurheartj/ehab777 · 2022 · External reference

Finerenone in heart failure with mildly reduced or preserved ejection fraction

10.1056/nejmoa2407107 · 2024 · External reference

Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function

10.1530/eje.1.01954 · 2005 · External reference

11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action

10.1152/physrev.00020.2012 · 2013 · External reference

The blood-brain barrier in aging and neurodegeneration

10.1038/s41380-022-01511-z · 2022 · External reference

Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography

10.1016/j.clpt.2006.02.004 · 2006 · External reference

Brain mineralocorticoid receptor in health and disease: from molecular signalling to cognitive and emotional function

10.1111/bph.15835 · 2022 · External reference

Oxidative stress and mineralocorticoid receptor signaling in the brain: possible therapeutic targets for dementia

2014 · External reference

Aldosterone and the mineralocorticoid receptor in the cerebral circulation and stroke

10.1186/2040-7378-4-21 · 2012 · External reference

Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats

10.1016/j.cardiores.2004.08.004 · 2004 · External reference

The pharmacokinetics of the nonsteroidal mineralocorticoid receptor antagonist finerenone

10.1007/s40262-023-01312-9 · 2023 · External reference

Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury

10.1097/fjc.0000000000000091 · 2014 · External reference

Association between use of spironolactone and risk of stroke in hypertensive patients: a cohort study

10.3390/ph16010057 · 2022 · External reference